The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1644
February 21, 2022
View Complete Issue         Table of Contents 2019 
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
February 21, 2022 (Issue: 1644)
The FDA has approved Apretude (ViiV Healthcare), an IM extended-release (ER) formulation of the integrase strand transfer inhibitor (INSTI) cabotegravir, for use every 2 months to prevent sexually acquired HIV-1 infection in at-risk adolescents...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
Article code: 1644d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.